Delipid Extracorporeal Lipoprotein Filter From Plasma (DELP) for Acute Hemorrhagic Stroke
Study Details
Study Description
Brief Summary
Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) has been found to improve neurological function and life ability of AIS patients and approved for the treatment of AIS by China Food and Drug Administration (CFDA). A recent study imply that the neuroprotective effect of DELP involved multiple neuroprotective mechanism such as anti-inflammation, free radical scavenging, and decreasing MMP-9. Based on the multiple mechanisms, the investigator argues that DELP may exert neuroprotective effect on acute cerebral hemorrhage (ACH). In this context, the prospective, random, open-label, blind-endpoint, multi-centre study is designed.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: DELP Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration |
Device: DELP
The blood was pumped into the PCS2 plasma separator through one side of the forearm vein. The plasma was separated by pump and then sent to the DELP system (Shanghai Jiangxia Blood Technology Co.). After purification, the plasma was returned to the patient via another forearm vein. The total treatment plasma volume was 800-1,000 mL; the anticoagulant 4% sodium citrate dehydrate solution with a ratio of 1:16 to plasma, was dropped before pumping. To prevent hypocalcemia, 500 mg CaCl2 diluted with 250 mL physiological saline was infused at a rate of 150 mL/h, in the first cycle of the returning blood transfusion.
|
| No Intervention: control group
|
Outcome Measures
Primary Outcome Measures
- Proportion of patients with modified Rankin Score 0 to 2 [Day 90]
the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome
Secondary Outcome Measures
- Proportion of patients with modified Rankin Score 0 to 1 [Day 90]
the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome
- distribution of modified Rankin Score [Day 90]
the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome
- Changes in National Institute of Health stroke scale (NIHSS) [24 hours and 2 weeks]
the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome
- the occurence of stroke or other vascular events [Day 90]
- the changes in cerebral hematoma volume [24 hours]
the hematoma volume was formulated by brain CT
- the severe adverse events [24 hours]
- the occurence of death due to any cause [2 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age: 18-80;
-
Spontaneous cerebral hemorrhage;
-
Deep supratentorial intracerebral hemorrhage (basal ganglia) with hematoma volume 5-40ml, or supratentorial lobar hemorrhages with hematoma volume 5-30ml;
-
NIHSS: 6-20;
-
Time from onset to DELP: 6-48 hours;
-
Premorbid mRS 0 or 1;
-
Signed informed consent;
Exclusion Criteria:
-
Secondary cerebral hemorrhage (secondary to trauma, tumor, vascular malformation, hemorrhage transformation of ischemic stroke, etc.);
-
Comatose patients on admission (GCS score 3-8 on the Glasgow Coma Scale);
-
Patients with intracerebral hemorrhage ruptured into the ventricle, which should be treated by surgery;
-
Planed surgery;
-
Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;
-
Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg), or hypotension (systolic blood pressure below 90mmHg or diastolic blood pressure below 60 mmHg);
-
Previous allergy to heparin or calcium;
-
Life expectancy is less than 6 months due to comorbidity
-
Infected at the venipuncture site
-
hypoproteinemia;
-
Unsuitable for this clinical studies assessed by researcher.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Neurology, General Hospital of Northern Theater Command | Shenyang | China | 110016 |
Sponsors and Collaborators
- General Hospital of Shenyang Military Region
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Y (2021) 38